Eli Lilly Buys AtaiBeckley for $3.8B | Business and Finance News

Eli Lilly just dropped a blockbuster $3.8 billion deal to acquire AtaiBeckley, betting big on a revolutionary new depression treatment that rebuilds brain connections — and it’s not just about the cash: shareholders get a 26% premium plus up to $2.50 per share if the experimental drugs hit key milestones. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3c1d0c5d538a743b